Cargando…
Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety
BACKGROUND: Migraine is one of the most debilitating medical conditions and has a high socioeconomic burden. As conventional therapeutic methods do not entirely alleviate the symptoms, new alternatives are being considered. OBJECTIVES: This study evaluates the efficacy and safety of zonisamide compa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253208/ https://www.ncbi.nlm.nih.gov/pubmed/28144450 http://dx.doi.org/10.5812/ircmj.23768 |
_version_ | 1782498135950491648 |
---|---|
author | Assarzadegan, Farhad Tabesh, Hanif Hosseini-Zijoud, Seyed-Mostafa Beale, Andrew David Shoghli, Arya Ghafoori Yazdi, Mahmood Mansouri, Behnam Hesami, Omid Beladi Moghadam, Nahid Delavar Kasmaei, Hosein |
author_facet | Assarzadegan, Farhad Tabesh, Hanif Hosseini-Zijoud, Seyed-Mostafa Beale, Andrew David Shoghli, Arya Ghafoori Yazdi, Mahmood Mansouri, Behnam Hesami, Omid Beladi Moghadam, Nahid Delavar Kasmaei, Hosein |
author_sort | Assarzadegan, Farhad |
collection | PubMed |
description | BACKGROUND: Migraine is one of the most debilitating medical conditions and has a high socioeconomic burden. As conventional therapeutic methods do not entirely alleviate the symptoms, new alternatives are being considered. OBJECTIVES: This study evaluates the efficacy and safety of zonisamide compared with sodium valproate in the management of migraine headaches. PATIENTS AND METHODS: In the current double-blind, parallel, randomized, controlled trial, 96 patients with a migraine diagnosis based on the international headache society (HIS) criteria were selected. They were divided randomly into two groups; the case group was given zonisamide, and sodium valproate was given to a control group. In addition to the side effects of the drugs, the severity, duration, and frequency of migraine attacks were evaluated at baseline and at three months. RESULTS: The 96 selected patients were divided randomly into two treatment groups (zonisamide n = 48, sodium valproate n = 48). Seven patients were excluded from analysis because of early dropout, leaving 89 (n = 45; n = 44) patients for analysis. While using zonisamide, six (13%) patients complained of fatigue, and two (4%) patients encountered noticeable appetite and weight loss. In the control group, five (11%) patients reported dizziness, and four (9%) patients faced obvious appetite and weight gain. Both drugs were considerably efficient in reducing further attacks. There was no statistically significant correlation between frequency or severity of migraine attacks and the drug used for treatment in three months of follow-up. CONCLUSIONS: Both medications are effective in reducing migraine attacks. It will be important to consider the drugs’ adverse effects and availability and patients’ medical and socioeconomic condition to select the appropriate treatment. |
format | Online Article Text |
id | pubmed-5253208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-52532082017-01-31 Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety Assarzadegan, Farhad Tabesh, Hanif Hosseini-Zijoud, Seyed-Mostafa Beale, Andrew David Shoghli, Arya Ghafoori Yazdi, Mahmood Mansouri, Behnam Hesami, Omid Beladi Moghadam, Nahid Delavar Kasmaei, Hosein Iran Red Crescent Med J Research Article BACKGROUND: Migraine is one of the most debilitating medical conditions and has a high socioeconomic burden. As conventional therapeutic methods do not entirely alleviate the symptoms, new alternatives are being considered. OBJECTIVES: This study evaluates the efficacy and safety of zonisamide compared with sodium valproate in the management of migraine headaches. PATIENTS AND METHODS: In the current double-blind, parallel, randomized, controlled trial, 96 patients with a migraine diagnosis based on the international headache society (HIS) criteria were selected. They were divided randomly into two groups; the case group was given zonisamide, and sodium valproate was given to a control group. In addition to the side effects of the drugs, the severity, duration, and frequency of migraine attacks were evaluated at baseline and at three months. RESULTS: The 96 selected patients were divided randomly into two treatment groups (zonisamide n = 48, sodium valproate n = 48). Seven patients were excluded from analysis because of early dropout, leaving 89 (n = 45; n = 44) patients for analysis. While using zonisamide, six (13%) patients complained of fatigue, and two (4%) patients encountered noticeable appetite and weight loss. In the control group, five (11%) patients reported dizziness, and four (9%) patients faced obvious appetite and weight gain. Both drugs were considerably efficient in reducing further attacks. There was no statistically significant correlation between frequency or severity of migraine attacks and the drug used for treatment in three months of follow-up. CONCLUSIONS: Both medications are effective in reducing migraine attacks. It will be important to consider the drugs’ adverse effects and availability and patients’ medical and socioeconomic condition to select the appropriate treatment. Kowsar 2016-04-30 /pmc/articles/PMC5253208/ /pubmed/28144450 http://dx.doi.org/10.5812/ircmj.23768 Text en Copyright © 2016, Iranian Red Crescent Medical Journal http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Research Article Assarzadegan, Farhad Tabesh, Hanif Hosseini-Zijoud, Seyed-Mostafa Beale, Andrew David Shoghli, Arya Ghafoori Yazdi, Mahmood Mansouri, Behnam Hesami, Omid Beladi Moghadam, Nahid Delavar Kasmaei, Hosein Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title | Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title_full | Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title_fullStr | Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title_full_unstemmed | Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title_short | Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety |
title_sort | comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253208/ https://www.ncbi.nlm.nih.gov/pubmed/28144450 http://dx.doi.org/10.5812/ircmj.23768 |
work_keys_str_mv | AT assarzadeganfarhad comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT tabeshhanif comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT hosseinizijoudseyedmostafa comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT bealeandrewdavid comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT shoghliarya comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT ghafooriyazdimahmood comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT mansouribehnam comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT hesamiomid comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT beladimoghadamnahid comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety AT delavarkasmaeihosein comparingzonisamidewithsodiumvalproateinthemanagementofmigraineheadachesdoubleblindrandomizedclinicaltrialofefficacyandsafety |